Insurance

How will changes to MediShield Life’s cancer coverage affect me?

Cancer coverage from MediShield Life is changing. With these changes, will I still need cancer insurance?

  • Phuan Wei Ning
  • |
  • Published on 01 Sep 2021

Did you know that Singapore pays more for cancer drugs as compared to that of Australia and South Korea? The spending on cancer drugs in Singapore has increased at a compounded rate of 20 per cent with MediShield Life paying out 50 per cent more for cancer treatments today as compared to that in 2017.1 As such, the government recently announced changes to MediSave and MediShield Life that will affect the coverage for cancer treatments. This is set to be effective from September 2022 with coverage from integrated shield plans changing from April 2023 onwards. These changes aim to moderate the increases in healthcare costs, in particular the cost of expensive cancer drug treatments.


These are the 3 main changes to your MediShield Life cancer coverage



Tell me more >


#1 Changes in claim amount for outpatient cancer drug treatments

Currently, MediShield Life allows a claim amount of $3,000 per month for all cancer drug treatments and services. This has however resulted in pharmaceutical companies raising prices to maximise the claims from MediShield Life.

Under the revised changes, claim amount will be changed to a range of $200 to $9,600 a month for drugs on the positive list only. Not only will this align the different cancer drug treatment costs but it will also allow for negotiations with pharmaceutical companies to lower their prices so their drugs can be included in the positive list. A separate claim limit of $1,200 per year will be created for outpatient cancer drug services to cover other expenses such as doctor consultations, scans, and blood tests.

Current
Revised
MediShield Life
$3,000 per month for all cancer drug treatments and services.
Range of $200 to $9,600 per month for cancer drug treatments on the positive list.

Additional $1,200 per year for cancer drug services.

MediSave
$1,200 per month for all cancer drug treatments and services.

Additional $600 per year for cancer scans.*

$1,200 per month for cancer drug treatments with MediShield Life claim limit above $5,400, and $600 per month for other treatments on the positive list.

Additional $600 per year for cancer drug services and/or other cancer scans.*

*MediSave can also be used for scans for post-treatment monitoring and radiotherapy patients.

(See "Cover Your “Missing” Hospitalisation Cash Benefits With These 3 Plans")


#2 Treatments on the MediShield Life positive list will get more subsidises from the government

The revised MediShield Life coverage will create a positive list for cancer drug treatments. This list will cover 90 per cent of the existing treatments in the public sector and will increase the percentage of subsidised Singaporean patients who can have their bills fully covered for their cancer drug treatments.2 This means that under the revised cancer coverage, close to 90 per cent of subsidised Singaporean patients who use treatments from the positive list will have their bills fully covered by subsidies and MediShield Life. This will be subjected to a 10 per cent co-payment for MediShield Life which can be paid via MediSave.

Additionally, while most Integrated Shield plans currently provide as-charged coverage for outpatient cancer drug treatments, this will change together with the revised MediShield Life coverage. From April 2023, Integrated Shield plans will only cover treatments that are on the MediShield Life positive list. Treatments not included in the positive list will not be covered by MediShield Life and MediSave.3


#3 More will be eligible for subsidies for specified high cost drugs

The Medication Assistance Fund (MAF) subsidies will be enhanced to include Singaporeans with a higher per capita household income (PCHI). Currently, Singaporeans will receive 50 to 75 per cent subsidies only if they have a monthly per capita household income below $2,800. Those with a PCHI above $2,800 will not be eligible for subsidies.

However, in future, the criteria to receive subsidies will be raised from the current PCHI of $2,800 to $6,500. This will help more Singaporeans to be eligible for these subsidies for specified high cost drugs.

Monthly per capita household income (PCHI)
Current
Revised
Between $0 to $2,000 PCHI
75%
75%
Between $2,000 to $2,800
50%
50%
Between $2,800 to $3,300
0%
50%
Between $3,300 to $6,500
0%
40%
Above $6,500
0%
0%

(See "What durians can teach you about your Critical Illness plan")


What these changes means for us

This means that Singaporeans and PRs who have MediShield Life can expect a lower amount payable via MediSave if we use clinically proven and cost-effective cancer drug treatments. This is the result of a lower pre-subsidy bill for cancer drug treatments together with higher subsidies given for treatments on the positive list. More Singaporeans will also be eligible for MAF subsidies with high cost drugs also included in future subsidies.

Illustration of a Singaporean with breast cancer, requiring one high-cost drug and one low-cost drug treatment.

Cancer drug bill
Current
Revised
Bill before subsidy
$3,130
$1,785
Subsidy given
$10
$890
Amount claimable from MediShield Life
$2,805
$800
Net amount payable
$315
$95
Amount payable via MediSave
$315
$95
Your out-of-pocket expenses
$0
$0

Information as shown by Ministry of Health.4

Do note that your MediShield Life is subjected to a 10% co-insurance. You may use your MediSave to pay this 10% co-insurance.


For patients currently undergoing cancer treatments

These changes to MediShield Life are set to be implemented only in September 2022. This will allow patients who are currently undergoing treatments to complete their current treatments and adjust their course of treatment accordingly.


With these revisions to MediShield Life allowing for higher coverage levels, will I still need a cancer plan?

The revised coverage from MediShield Life will allow higher coverage for cancer treatments. However, it is important to understand that cancer insurance serves a different purpose. This is because while MediShield Life covers for cancer treatments, coverage is given on a reimbursement basis. This means that if your treatment costs $1,000, MediShield Life will reimburse you $1,000 and nothing more. As such, while MediShield Life will cover your hospitalisation and selected outpatient treatments, it will not provide any income replacement. This is when a cancer plan comes into play.

Unlike MediShield Life that operates on a reimbursement basis, cancer plans will provide a lump sum pay-out when conditions are fulfilled. This can either be a full 100 per cent pay-out given upon diagnosis or may be given in staggered amounts based on the severity of your illness. This can then serve as your income replacement during your recovery period. Alternatively, your pay-outs from a cancer plan can also be used for your daily expenses, to pay for any household expenses, or even to pay for a certain treatment that may not be included in MediShield Life’s positive list.

MediShield Life
Cancer insurance plans
Type of coverage
Reimbursement basis
Lump sum pay-out
Administered by
CPF board
Private insurers
Typically used for
Hospitalisation coverage and specified outpatient treatments.
Income replacement during your recovery period. Pay-outs can also be used for long-term care costs, daily expenses or any other uses as you deem fit.

(See "Cheap Cancer Insurance Singapore 2021")


Cancer insurance plans available on FSMOne:

Name of plan
Allianz Cancer Protect
FWD Cancer Insurance
MSIG CancerCare Plus
NTUC Cancer Protect
TM Protect Cancer
Annual premiums^ (after discounts)
304.08
$161.19
$155.22
$334.60
$263
Ongoing promotions
30% off first year premiums. T&Cs apply.
35% off with promo code "IFAST".

20% off premiums. Valid until 31 October 2021. T&Cs apply.
-
-

^Profile: Age 40, non-smoker male for $100,000 sum assured. Premiums shown are before discounts and is accurate as of 6 December 2021.


Let FSMOne help you with your insurance planning

Over 10,300 users trust FSMOne with their insurance planning.

Live better, safer. Get a free review from our advisers today!

Get Started >


Click here to find out how much protection you need


Available Products on FSMOne Insurance

Term Life, Whole Life, Critical Illness, Annuity, Health, Endowment, General Insurance (Personal and Commercial)


from AIG, Allianz, Chubb, Etiqa Insurance, FWD Insurance, Great Eastern, Manulife, NTUC Income, QBE, Sompo and Tokio Marine Life Insurance


*Please check with our advisory team if the product you want is available on FSMOne Insurance


Interested to learn more? Check out these articles:

Is CPF Life enough for me to retire?

Should I switch from Eldershield to CareShield Life?

Is maternity insurance a must-have for all expecting mothers?

Best Personal Accident Insurance 2021

How much should I be spending on insurance for my child?


----

1 Source: https://www.moh.gov.sg/docs/librariesprovider5/default-document-library/annex-a12145e9763d74fe587ad80b942d86fdb.pdf

2 https://www.moh.gov.sg/home/our-healthcare-system/medishield-life/what-is-medishield-life/what-medishield-life-benefits/outpatient-cancer-drug-list

3 Source: https://www.moh.gov.sg/news-highlights/details/government-enhances-subsidies-to-improve-affordability-of-cancer-treatment_17Aug2021

4 Source: https://www.moh.gov.sg/docs/librariesprovider5/default-document-library/annex-b880319b554ef4ba881959cd09d6f32b4.pdf

All materials and contents found in this site are strictly for general circulation and informational purposes only and should not be considered as an offer, or solicitation, to deal in any of the funds or products found/identified in this site. While iFAST Financial Pte Ltd ("IFPL") has tried to provide accurate and timely information, there may be inadvertent delays, omissions, technical or factual inaccuracies and typographical errors. Any opinion or estimate contained in this report is made on a general basis and neither IFPL nor any of its servants or agents have given any consideration to nor have they or any of them made any investigation of the investment objective, financial situation or particular need of any user or reader, any specific person or group of persons. You should consider carefully if the products you are going to purchase are suitable for your investment objective, investment experience, risk tolerance and other personal circumstances. If you are uncertain about the suitability of the investment product, please seek advice from a financial adviser, before making a decision to purchase the investment product. Past performance is not indicative of future performance. The value of the investment products and the income from them may fall as well as rise. Opinions expressed herein are subject to change without notice. In respect of any matters arising from, or in connection with the said research analyses or research reports, recipients of the report are to contact IFPL at 10 Collyer Quay, #26-01 Ocean Financial Centre Building, Singapore 049315, or by telephone at +65 6557 2853. Where the report contains research analyses or research reports from a foreign research house and if the recipient of such research analyses or research reports is not an accredited investor, expert investor, institutional investor or an ex-accredited investor, IFPL accepts legal responsibility for the contents of such analyses or reports to such persons only to the extent as required by law. Please note that only certain security(ies) herein are available to all investors, while the rest are only available for certain persons to invest in, such as Accredited Investors (as defined in the Securities and Futures Act) or one who invests at least S$200,000 (or its equivalent currency) per transaction. To qualify as an Accredited Investor, one needs to submit a declaration form and certain relevant supporting documents, according to iFAST’s prevailing policies and procedures.

Please read our full disclaimers on the website at ( https://secure.fundsupermart.com/fsmone/policies/328125/investment-account-terms-&-conditions).

iFAST Financial Pte Ltd (IFPL) (registered address: 10 Collyer Quay #26-01 Ocean Financial Centre Singapore 049315, Telephone: 6557 2000) holds the Financial Advisers Licence issued by the Monetary Authority of Singapore ('MAS') to conduct regulated activities of advising on securities, marketing of collective investment schemes and arranging of any contract of insurance in respect of life policies, other than a contract of reinsurance and the Capital Markets Services Licence issued by the MAS to conduct regulated activities of dealing in securities and providing custodial services for securities. While IFPL has made every effort to ensure the independence of the report's contents, IFPL's nature of business is such that IFPL and its connected and associated entities together with their respective directors, officers and staff may be involved in providing dealing or investment-related services in the abovementioned securities, and have taken or may take positions in the securities mentioned in this report, and may also act as the principal for any buy or sell trades.


Ways to Invest with FSM Global
Why FSM Global
Don't have an account with us?
Open an account here
Need Financial Advice?
Make an appointment
Related Articles More

We use cookies If you close this message or continue to use this site, you will consent to the use of Cookies, unless you choose to disable them. Click on our Privacy Policy to understand more.